{"url_path":"/sec/cocp/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-023377-index.html","accession_number":"0001493152-26-023377","cik":"0001412486","ticker":"COCP","issuer_name":"Cocrystal Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-023377-index.html","primary_entity_key":"0001412486","primary_entity_name":"Cocrystal Pharma, Inc."},"word_count":74,"has_tables":true,"body_markdown":"**ITEM\n5. OTHER INFORMATION**\n\n \n\nDuring\nthe three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted\nor terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative\ndefense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 arrangement” as defined in Item 408(c)\nof Regulation S-K.\n\n \n\n11"}